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Abstract 
Background: Rosetting, namely the capacity of the Plasmodium falciparum‑infected red blood cells to bind unin‑
fected RBCs, is commonly observed in African children with severe malaria. Rosetting results from specific interactions 
between a subset of variant P. falciparum erythrocyte membrane protein 1 (PfEMP1) adhesins encoded by var genes, 
serum components and RBC receptors. Rosette formation is a redundant phenotype, as there exists more than one 
var gene encoding a rosette‑mediating PfEMP1 in each genome and hence a diverse array of underlying interactions. 
Moreover, field diversity creates a large panel of rosetting‑associated serotypes and studies with human immune sera 
indicate that surface‑reacting antibodies are essentially variant‑specific. To gain better insight into the interactions 
involved in rosetting and map surface epitopes, a panel of monoclonal antibodies (mAbs) was investigated.
Methods: Monoclonal antibodies were isolated from mice immunized with PfEMP1‑VarO recombinant domains. 
They were characterized using ELISA and reactivity with the native PfEMP1‑VarO adhesin on immunoblots of reduced 
and unreduced extracts, as well as SDS‑extracts of Palo Alto 89F5 VarO schizonts. Functionality was assessed using 
inhibition of Palo Alto 89F5 VarO rosette formation and disruption of Palo Alto 89F5 VarO rosettes. Competition ELISAs 
were performed with biotinylated antibodies against DBL1 to identify reactivity groups. Specificity of mAbs reacting 
with the DBL1 adhesion domain was explored using recombinant proteins carrying mutations abolishing RBC bind‑
ing or binding to heparin, a potent inhibitor of rosette formation.
Results: Domain‑specific, surface‑reacting mAbs were obtained for four individual domains (DBL1, CIDR1, DBL2, 
DBL4). Monoclonal antibodies reacting with DBL1 potently inhibited the formation of rosettes and disrupted Palo Alto 
89F5 VarO rosettes. Most surface‑reactive mAbs and all mAbs interfering with rosetting reacted on parasite immu‑
noblots with disulfide bond‑dependent PfEMP1 epitopes. Based on competition ELISA and binding to mutant DBL1 
domains, two distinct binding sites for rosette‑disrupting mAbs were identified in close proximity to the RBC‑binding 
site.
Conclusions: Rosette‑inhibitory antibodies bind to conformation‑dependent epitopes located close to the RBC‑
binding site and distant from the heparin‑binding site. These results provide novel clues for a rational intervention 
strategy that targets rosetting.
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Background
Sequestration of mature Plasmodium falciparum intra-
erythrocytic stages in the microvasculature is a major 
contributor to falciparum pathogenesis [1, 2]. The best-
characterized parasite factor implicated in cytoadherence 
is the family of P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) variant adhesins encoded by the 
approximately 60-member var gene family [3]. PfEMP1 
molecules comprise a large surface-exposed N-terminal 
region containing a suite of modules called Duffy-Bind-
ing Like (DBL) domains and Cysteine-rich Inter-Domain 
Regions (CIDR), a single transmembrane segment and a 
cytoplasmic C-terminal domain. DBL and CIDR domains 
are highly variable within the PfEMP1 family but they 
can be assigned to a limited number of classes according 
to distinct sequence signatures [4–6]. The variability in 
sequence and domain organization in PfEMP1 variants 
[6] provides the parasite with the capacity to bind to an 
array of host receptors and to evade host immunity [3].
The capacity of infected red blood cells (iRBCs) to cyto-
adhere to uninfected RBC, i.e., rosetting, has been associ-
ated with severe malaria in African children, with higher 
frequency of rosette-forming parasites and larger rosettes 
than in uncomplicated malaria [7–11]. Rosetting is also 
associated with an elevated infecting parasite biomass 
[10] and an increased multiplication rate in a non-human 
primate model [12]. Rosetting involves specific interac-
tions between a subset of PfEMP1 adhesins [5, 6, 13–15], 
serum factors [15–22] and a variety of RBC receptors [20, 
23–26]. Using vaccination or soluble inhibitors to tar-
get rosetting is thus an attractive strategy against severe 
malaria pathology.
To better understand critical molecular interactions 
and immunologic determinants implicated in rosetting, 
experimental models are needed. The Palo Alto VarO, a 
clonal rosetting line infectious for the Saimiri sciureus 
monkey [12], has been developed as a monovariant cul-
ture, in which a large majority (90–95  %) of the iRBCs 
express the Palo Alto varO gene [13]. The PfEMP1-VarO 
extracellular region has five DBL domains (DBL1–5) and 
one CIDR domain. All six domains, as well as the dou-
ble DBL1-CIDR Head domain, have been produced as 
recombinant proteins [13, 20, 27, 28]. RBC binding has 
been mapped to DBL1α and the ABO blood group deter-
minants have been identified as the erythrocyte recep-
tor [20]. This model was used to explore the immune 
response of humans living in endemic areas showing 
elevated seroprevalence in Senegalese [13] and Beni-
nese settings [29]. Two important features emerged from 
these studies, namely that the surface-reacting antibod-
ies acquired by humans exposed to malaria were variant-
specific [30] and that there were no rosette-disrupting 
antibodies in children [29].
Previous work has shown that DBL1, CIDR1, DBL2, 
DBL4 and the Head PfEMP1-VarO domains elicited 
antibodies reacting with the Palo Alto VarO iRBC sur-
face. The work reported here aims to gain insight into 
the surface epitopes of PfEMP1-VarO using monoclonal 
antibodies (mAbs) isolated from mice immunized with 
these recombinant domains. The mAbs were character-
ized with respect to reactivity with the iRBC membrane-
anchored PfEMP1-VarO by surface immunofluorescence 
and immunoblots of SDS-extracts of Palo Alto VarO 
iRBCs. Their functionality was assessed using rosette dis-
ruption and inhibition of rosette formation assays. The 
reactivity of surface-reacting mAbs specific for DBL1 
was analysed using a panel of mutant domains, highlight-
ing the existence of two distinct binding sites of potent 
rosette-disrupting mAbs. These results provide novel 
clues for the design of anti-rosetting strategies.
Methods
Parasites and rosetting assays
89F5 Palo Alto VarO parasites were cultivated as 
described in O+ RBC in RPMI 1640 medium containing 
l-glutamine and 25 mM HEPES (called hereafter RPMI) 
and supplemented with 10  % AB+ human serum [13]. 
Rosetting parasites were enriched once a week on ice-
cold Ficoll and rosetting rate was kept >90 % by panning 
on a specific monoclonal antibody as described [13, 30]. 
Procedures and reagents for monovariant culture, and 
rosette purification have been published in detail [31].
For inhibition of rosette formation, monovariant VarO 
cultures were treated with 0.3  M Alanine (in 10  mM 
Hepes) to eliminate all mature stages. The cultures were 
then adjusted to 5  % parasitemia, 2  % hematocrit in 
RPMI, 10 % human AB+ serum and 100 µL aliquots (ring 
stages) were incubated in 96-well plates at 37 ℃ for 24 h 
with serial dilutions of monoclonal IgG or control rea-
gents (diluted in RPMI, 10 % human AB+ serum). After 
this 24-h cultivation, parasite nuclei were labelled with 
10 µg mL−1 Hoechst 33342 (Molecular Probes® Thermo 
Fisher Scientific) for 10 min at 37 ℃ and an aliquot of the 
culture was examined using a fluorescence microscope. 
The number of iRBCs engaged in rosettes were scored by 
examining 200 iRBCs. The rosetting rate was calculated 
as the percent of mature stage iRBCs engaged in rosettes. 
Details are described in [31].
The rosette disruption assay has been described in 
detail elsewhere [32, 33]. Briefly, monovariant Palo Alto 
89F5 VarO rosette preparations, adjusted to 5  % para-
sitemia, 5  % hematocrit in RPMI, 10  % human AB+ 
serum were incubated 30  min at 37 ℃ with serial dilu-
tions of monoclonal IgG or control reagents (diluted in 
RPMI, 10  % human AB+ serum). At the end of incuba-
tion, mature stages engaged in rosettes or free of bound 
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RBCs were numerated by microscopy (for details see [31, 
32]). The rosetting rate was then evaluated as above.
Production of recombinant VarO domains
The recombinant domains used to immunize mice and 
isolate mAbs are shown in Table 1, which indicates their 
type alongside some sequence features. Cloning of the re-
codoned DBL3 and DBL5 domains (which did not elicit 
surface-reacting antisera) has been described previously 
[20]. The various DBL1 mutants have been described in 
[20, 28]; the Genbank accession number of the wild type 
protein sequence is EU908205. Recombinant proteins 
were stored in aliquots at −80 ℃ and thawed before use. 
This, however, caused internal cleavage in some proteins.
Production of monoclonal antibodies (mAbs)
MAbs were obtained from OF1 mice immunized with 
bDBL1, eHead, pCIDR1, bDBL2, and eDBL4 (10  µg/
dose injected subcutaneously at 3-week intervals, mixed 
with complete Freund’s adjuvant for the first dose and 
incomplete for the boosters) [33]. Mice with high spe-
cific IgG titres against the immunogen received an 
intraperitoneal boost immunization 4  days before being 
sacrificed for splenic B cell fusion, which was performed 
as described [34]. For bDBL1, culture supernatants 
were screened for VarO iRBC surface reactivity by flow 
cytometry (hybridomas D15-50, D15-68, E20-76). For 
pCIDR, eHead, bDBL2, and eDBL4, culture superna-
tants were first screened by ELISA on the recombinant 
protein and positive culture supernatants were then 
tested by surface-IFA/flow cytometry against VarO 
iRBCs. Positive hybridomas were cloned by limiting 
dilution and screened for ELISA and VarO iRBC sur-
face reactivity. Hybridomas BD20E4 and BDEE10 were 
custom-made by RD Biotech (Besançon, France), who 
performed the screening by ELISA on the recombinant 
protein. Clones were then selected on the basis of VarO 
iRBC surface reactivity by flow cytometry in the authors’ 
laboratory. Monoclonal IgG were precipitated with 50 % 
ammonium sulfate from ascitic fluid, centrifuged and 
dialyzed against PBS. Monoclonal Ig class and sub-class 
were determined by ELISA using the isotrip mouse mAb 
isotyping kit (Roche). Monoclonal IgG were purified 
using the Melon™ gel monoclonal IgG purification kit 
(Thermo Fisher Scientific) as recommended by the man-
ufacturers. D15-50, E20-76 and BD20E4 IgG were bioti-
nylated using EZ-link sulfo-NHS-biotin (Thermo  Fisher 
Scientific) and centrifuged through Zeba™ spin desalting 
columns (Thermo Fisher Scientific) according to the sup-
plier’s recommendations. The concentration of the bioti-
nylated antibodies was evaluated using the Pierce BCA 
protein assay kit (Thermo Fisher Scientific).
Ethics
The study was carried out in strict accordance with the 
recommendations in the guide for the care and use of 
laboratory animals of the Institut Pasteur and complied 
with the French [35] and European Union guidelines for 
the handling of laboratory animals [36]. Animal care and 
handling was approved by the Ministère de l’Agriculture 
et de la Pêche (Ref 107503056792, issued to OMP) and 
the protocols and procedures approved by the Direc-
tion Départementale des Services Vétérinaires du Préfet 
de Police de Paris (clearance number C75-273 issued to 
OMP). All animal experiments were planned and exe-
cuted in order to minimize animal suffering.
ELISA assays
ELISA plates (Nunc maxisorp) were coated with 100 μL/
well of a solution of 0.2  μg  mL−1 recombinant protein 
in PBS, overnight at 4 ℃. Non-specific absorption was 
blocked with 200 μL blocking buffer (PBS, 5 % w/v non-
fat milk) for 1 h at 37 ℃, 100 μL serial dilutions of sera 
(in PBS, 2.5 % non-fat milk, 0.05 % Tween-20) were incu-
bated 1 h at 37 ℃. Plates were then washed three times 
with washing buffer (PBS, 0.1  % Tween-20) and incu-
bated for 1 h at 37 ℃ with horseradish peroxidase-con-
jugated goat anti-mouse IgG (H + L) (Promega) diluted 
Table 1 List of recombinant PfEMP1-VarO domains, sequence features and expression systems used to immunise mice
VarO domain Amino acid position in the  
complete protein sequence
Sequence features (number 
of potential N-glycosylation 
sites mutated S/T to A)
Expression system Name  
used
References
DBL1α1.6 1–487 Recodoned (7) Baculovirus/insect cells bDBL1 [13]
E. coli/pMAL‑c2X eDBL1 [27]
CIDRγ6 399–835 Recodoned (1) Baculovirus/insect cells bCIDR [33]
508–787 Recodoned (1) P. pastoris/pPICZαA pCIDR [20]
Head (DBL1α1.6–CIDRγ6) 2–716 Recodoned (8) E. coli/pMAL‑c2X eHead [20]
DBL2β7 821–1242 Recodoned (2) Baculovirus/insect cells bDBL2 [33]
DBL4ε5 1608–2014 Recodoned (3) E. coli/pMAL‑c2X eDBL4 [20]
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at 1/3000 or anti-rabbit IgG (Promega) diluted 1/3000 in 
washing buffer. Plates were washed three times before 
incubation for 5 min at RT with 100 μL TMB/H2O2 sub-
strate (KPL). The enzymatic reaction was stopped by 
addition of 100 μL 1 M H3PO4. Absorbance was meas-
ured at 450–655 nm. Each serum dilution was tested in 
duplicate.
For competition ELISA with biotinylated IgG, plates 
coated with 1 μg mL−1 bDBL1 were incubated with unla-
belled monoclonal D15-50, D15-68, E20-76, BD20E4, 
BDEE10, M21-17 and M21-30 IgG at saturating concen-
tration (50 μg mL−1) for 2 h at 37 ℃. After four washes 
with PBS, 0.1  % Tween-20, biotinylated D15-50, E20-76 
or BD20E4 IgG were added to individual wells at a con-
centration previously determined to generate a signal of 
approximately 1 OD after incubation at 4 ℃ for 20 min. 
After this 20-min incubation and four successive washes 
with washing buffer, streptavidin-conjugated horserad-
ish peroxidase (Thermo Fisher Scientific) diluted 1/1000 
was added to each well and incubated for 60 min at 37 ℃ 
and after four successive washes with washing buffer, the 
bound enzyme was revealed as above.
Immunoblots
Immunoblots of non-reduced recombinant proteins were 
prepared as described [33]. Briefly, proteins were frac-
tionated on 4–12 % SDS-PAGE gradient and transferred 
to a nitrocellulose membrane (Amersham). The mem-
branes were blocked with PBS, 5 % non-fat milk for 1 h at 
room temperature and probed with diluted sera in PBS, 
2.5 % non fat milk, 0.05 % Tween-20. After three washes 
with PBS, 0.1  % Tween-20, the blot was incubated with 
anti-mouse IgG (H  +  L) conjugated to alkaline phos-
phatase (Promega) diluted 1/10,000 in PBS, 2.5  % non 
fat milk, 0.05 % Tween-20 for 1 h at room temperature, 
washed and binding was revealed using Western Blue® 
stabilized substrate (Promega) as recommended by the 
supplier.
Immunoblots of Palo Alto 89F5 VarO crude extracts 
were prepared as described [37] from rosettes selected 
on ice-cold Ficoll and enriched on magnetic columns 
(VarioMacs and CS MACS separation columns, Miltenyi 
Biotec) to obtain a preparation containing >95 % iRBCs 
at the mature stage [31]. For SDS-extracts preparations, 
the highly enriched parasite preparation was first resus-
pended in 20 volumes of Triton buffer (PBS, 1 % Triton 
X-100, 2 mM EGTA, complete EDTA-free protease cock-
tail inhibitors from Roche diagnostics) for 30 min at 4 ℃ 
and centrifuged at 16,100g at 4 ℃ for 30 min. The pellet 
was then washed twice with Triton buffer and insoluble 
proteins were extracted with PBS, 2  % sodium dodecyl 
sulfate (SDS) supplemented with protease inhibitors for 
30 min at RT under a rotation movement and centrifuged 
at 16,100g for 30  min at 4 ℃. The supernatant was col-
lected and diluted tenfold with PBS, 10  % Triton. The 
SDS-soluble protein extract was kept at −80 ℃ until use. 
Immunoblots prepared from reduced or non-reduced 
SDS-extracts were processed as above.
Surface immunofluorescence assay
Antibodies (IgG) reacting with the PfEMP1-VarO pro-
tein displayed on iRBC surface were monitored by 
indirect immunofluorescence using flow cytometry or 
fluorescence microscopy as described [33]. Immunofluo-
rescence staining was analysed as described [33].
Results
Isolation and characterization of monoclonal antibodies
Hybridomas were generated from mice immunized with 
bDBL1, pCIDR, bDBL2, eDBL4 or the eHead domain 
(Table 1). Initial screening for surface reactivity identified 
mAbs E20-76, D15-50 and D15-68 from mice immunized 
with bDBL1. Screening of subsequent fusions was done 
stepwise, first by ELISA on the immunizing antigen and 
then by VarO iRBC surface reactivity. Overall seven anti-
bDBL1, two anti-pCIDR, two anti-bDBL2 and one anti-
DBL4 mAbs were studied in detail. All anti-bDBL1 mAbs 
and the anti-pCIDR mAbs were IgG1, while mAb G8-49 
was classified as IgG2b and mAbs B12-15, B12-42 and 
D18-94 were IgG2a (Table 2).
MAbs M21-17 and M21-30 reacted with bDBL1 and 
eDBL1 by ELISA but not with the Palo Alto 89F5 VarO 
iRBC surface (Fig.  1a). All other mAbs studied were 
surface-reactive as well as reacting by ELISA on the cog-
nate domain. Figure 1a shows profiles of surface reactiv-
ity assessed by flow cytometry and Fig.  1b the titration 
curves of individual mAbs by flow cytometry.
Domain specificity
All mAbs reacted by ELISA with the cognate domain 
irrespective of the expression system (Fig. 2a). Immunob-
lotting showed that the anti-DBL1 mAbs D15-50, E20-76 
and BDEE10 reacted with the cognate recombinant anti-
gen and not with the other domains (Fig. 2b). There was 
very faint cross-reactivity of the anti-CIDR mAb N6-37 
with eDBL1; this was not observed with mAb G8-49 
(raised to eHead), which presented faint cross-reactivity 
to eDBL4. MAb B12-42 (raised to bDBL2) showed some 
faint cross-reactivity with eDBL1 while mAb D18-94 
(raised to eDBL4) cross-reacted with pCIDR.
Reactivity with the PfEMP1 protein on parasite 
immunoblots
All mAbs reacted on immunoblots of non-reduced total 
extracts of Palo Alto 89F5 VarO iRBCs but only mAbs 
BDEE10, G8-49 and D18-94 reacted with the reduced 
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extract (Fig.  3a shows the pattern of reactivity of seven 
mAbs with the non-reduced total extract, see also 
Table 2). The surface-displayed PfEMP1 antigen is a type 
I membrane protein that can be solubilized in 0.5 % SDS. 
Probing of immunoblots of SDS-extracts showed that 
mAbs M21-17 and M21-30, which reacted with PfEMP1-
VarO on immunoblots of non-reduced total parasite 
extracts (Fig.  3a, lanes 1 and 2, respectively), failed to 
react on the SDS-solubilized, membrane-anchored 
PfEMP1-VarO (Fig.  3b, c, lanes 1 and 2, respectively). 
This suggests that these mAbs recognize an epitope that 
is not present on the membrane-anchored PfEMP1-
VarO. All surface-reacting mAbs tested reacted with the 
SDS-extracted PfEMP1-VarO and this reaction was abol-
ished upon reduction of the parasite proteins (Fig. 3b, c). 
Table  2 summarizes ELISA titres, parasite immunoblot 
reactivity and surface reactivity of the various mAbs.
Competition ELISA
Competition ELISAs using individual biotinylated anti-
bDBL1 mAbs were used to classify the mAbs. Biotinyla-
tion reduced the ELISA titre of each mAb on the cognate 
antigen by approximately threefold as indicated by the 
shift of the antigen-dose dependent titration curves (see 
Additional file  1: Figure S1) but as its impact was simi-
lar for the three mAbs, competition ELISAs were carried 
Fig. 1 Surface reactivity of anti‑PfEMP1‑VarO mAbs assessed by flow cytometry. a Mean fluorescence intensity (MFI) of each anti‑PfEMP1 VarO 
mAb reacting with the PfEMP1‑VarO protein displayed on the surface of monovariant Palo Alto 89F5 VarO rosette‑forming iRBC (trophozoite stage). 
Each mAb was used at 10 μg mL−1 and surface reactivity was monitored by indirect immunofluorescence using a goat anti‑mouse IgG Alexa Fluor 
488‑conjugated antibody. The shaded histograms show labelling with a pool of mouse non‑immune sera. b Titration curves of surface reactivity for 
individual mAbs, which are colour-coded as indicated
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Fig. 2 Reactivity of anti‑PfEMP1‑VarO mAbs on cognate and other domains assessed by ELISA and immunoblot. a ELISA titration curves of mAbs 
on the cognate domain. ELISAs were carried out as described in the “Methods” section. The antigen used to coat the plate was as follows: eDBL1 
for mAbs D15‑50, D15‑68, E20‑76, BD20E4, BDEE10, pCIDR for N6‑37 and G8‑49, eDBL2 for B12‑15 and B12‑42, eDBL4 for D18‑94. Each dilution was 
tested in duplicate. b Specificity of the mAbs raised to PfEMP1‑VarO‑derived recombinant domains assessed by immunoblot on the cognate and 
other PfEMP1‑VarO‑derived recombinant domains. Recombinant domains (50 ng each) were separated on 4–12 % SDS gels under non‑reducing 
conditions and immunoblotted. Eight immunoblots were prepared in parallel and loaded with eDBL1, eHead, pCIDR, bDBL2, eDBL3, eDBL4, and 
eDBL5 as indicated. Blots were incubated with individual mAbs (20 μg mL−1) as indicated
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out. This distributed the mAbs into three non-competing 
sets: (i) D15-50 and E20-76; (ii) BD20E4 and BDEE10; 
and (iii) M21-30 and M21-17, although each biotinylated 
mAb competed best with its non-biotinylated cognate 
mAb (see Additional file  2: Table S1). As M21-30 and 
M21-17 did not react with the iRBC surface, they were 
not studied further with regard to functionality.
Functional characterization: inhibition of rosette formation 
and rosette disruption
To assess the capacity of the mAbs to interfere with VarO 
rosetting, two functional assays were carried out with 
monovariant Palo Alto 89F5 VarO cultures, i.e., cultures 
in which >90 % of the mature stages formed rosettes that 
reacted with any of the anti-VarO mAbs. Data are sum-
marized in Table 2.
Inhibition of rosette formation was assessed by cultivat-
ing synchronized ring stages for 24 h in the presence of a 
mAb and numerating the rosettes formed in presence of 
the mAbs at the end of this time period when the para-
sites reached the trophozoite-early schizont stage. Only 
mAbs reacting with DBL1 were able to efficiently prevent 
the formation of rosettes (Fig.  4a). D15-50, E20-76 and 
BD20E4 had similar rosette inhibition profiles and pre-
vented 95–100 % rosette formation at a concentration of 
1 μg mL−1. This high level of inhibition was observed with 
10 μg mL−1 polyclonal rabbit IgG raised to bDBL1. D15-68 
less efficiently prevented formation of VarO rosettes with 
low inhibition rates at 1 μg mL−1 and the least potent anti-
DBL1 mAb was BDEE10. MAbs against the downstream 
domains failed to inhibit formation of rosettes at a concen-
tration of 10 μg mL−1. Data are summarized in Table 2.
The capacity to disrupt VarO rosettes, i.e., break the 
interactions between the iRBC and the uninfected RBC, 
was evaluated by incubating monovariant cultures with 
the mAbs and numerating the iRBCs remaining engaged 
in rosettes after this incubation. This showed that the 
three mAbs that had similar inhibition profiles differed 
in their capacity to disrupt rosettes (Fig.  4b). BD20E4 
was the most potent disrupter, with 50  % disruption at 
0.7 μg mL−1 and 100 % disruption at 10 μg mL−1. MAb 
D15-50 was 100 % disruptive at 100 μg mL−1 concentra-
tion and only 60 % disruptive at 10 μg mL−1. MAb E20-
76, on the other hand, was only 60  % disruptive at the 
highest concentration tested (100 μg mL−1). Surprisingly, 
BDEE10 displayed a much higher disruption capacity 
than D15-68. The other mAbs had no or quite marginal 
rosette-disrupting capacity (Fig. 4b; Table 2).
Epitope specificity
To investigate epitope specificity  of anti-DBL1 mAbs, 
reactivity of four mAbs (D15-50, E20-76, BD20E4, 
BDEE10) with a panel of recombinant eDBL1 pro-
teins was analysed (Table  3). Previous work has shown 
that the eDBL1-s construct lacking the two C-terminal 
cysteine residues had essentially the same immunore-
activity with polyclonal sera raised to the longer bDBL1 
or eDBL1 constructs [33]. This C-terminal deletion had 
limited impact on RBC binding [20, 28]. It however had 
a significant impact on binding of BD20E4. BD20E4 titres 
Fig. 3 Reactivity of mAbs with the native parasite PfEMP1‑VarO protein on immunoblot of Palo Alto 89F5 VarO extracts. Non‑reduced total schizont 
extract (a); reduced SDS extract of schizonts (b); non‑reduced SDS extract of schizonts (c). Strips from each blot were reacted with 50 μg mL−1 
mAbs as follows: mAb M21‑17 (lane 1), mAb M21‑30 (lane 2), mAb E20‑48 (lane 3), mAb E20‑76 (lane 4), mAb D15‑50 (lane 5), mAb D15‑68 (lane 6), 
mAb N6‑37 (lane 7), and mAb B12‑15 (lane 8). The arrow indicates PfEMP1‑VarO
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and reactivity were substantially lower on all constructs 
lacking 16 residues at the C-terminus and consequently 
the Cys19–Cys20 disulfide bond (Fig. 5b). Such a reduced 
reactivity with shorter constructs was not observed with 
the other mAbs (Fig. 5a, c, d; Table 3). 
Reactivity with a set of recombinant proteins carrying 
specific mutations introduced into the eDBL1-s parent 
sequence was then analysed. Some of these mutations 
reduced heparin binding [28], while others abolished 
RBC binding, localizing the heparin-binding site and the 
RBC-binding site to opposite sides of the DBL1 domain 
[28]. Importantly, the various mutations have no major 
effect on conformation, as indicated by unaltered CD 
spectra [28, 20]. Although none of the mutations abol-
ished reactivity of the set of mAbs tested, some did 
reduce binding as shown by reduced ELISA values and 
titres. The impact of specific mutations on mAb reac-
tivity showed a clear partitioning (Fig.  5). D15-50 and 
E20-76 had a reduced binding to Mut2 (panels a and c, 
respectively), whereas binding of BD20E4 and BDEE10 
to Mut4 was reduced (panels c and d, respectively). 
Cleavage of Mut10 by Factor Xa after residue R69 greatly 
reduced binding of D15-50 and E20-76 (panels e and g, 
respectively) but had no impact on binding of BD20E4 
and BDEE10 (panels f and h, respectively). These data 
indicate that the mAbs bind to two adjacent DBL1 sur-
face areas involved in RBC binding, since both the muta-
tions harbored by Mut2 and Mut4 as well as Factor Xa 
cleavage after residue R64 were shown to abolish RBC 
binding [20]. There was no significant impact of the 
mutations of the heparin-binding site on mAb binding 
(Table 3).
Reactivity of the mAbs was further tested on a second 
panel of mutants derived from the eDBL1-s wild type 
sequence reported previously [20]. This included in par-
ticular specific mutations of the computationally derived 
ABO blood group binding site, introduced as single 
mutations (K95A) or double mutations (F145A K216A). 
None of these had any significant impact on the binding 
of the four mAbs (Additional file 3: Table S2, Figure S2).
Fine binding specificity differences could be observed 
within each mAb pair. The reduced binding of BD20E4 
with the shorter constructs compared to the longer ones 
(eDBL1, Mut11, eHead) was not observed for BDEE10 
and the impact of some mutations on binding differed 
between these mAbs (Fig. 5; Table 3). A trend for distinct 
mutant-specific reactivity was also observed for D15-
50 and E2076. Binding of E20-76 to factor Xa-cleaved 
Mut10 was reduced compared to D15-50 (Fig.  5g, e 
respectively). Moreover, compared to D15-50, E20-76 
displayed reduced binding to Mut11, Mut1, Mut2, Mut4, 
and Mut5, but enhanced binding to Mut8 (summarized 
in Table 3). In summary, binding profiles were specific for 
each of the two pairs identified by competition ELISA, 
and within each pair, specific for each mAb.
Mapping of the binding site on the crystal structure of Palo 
Alto DBL1-VarO
The structures of the DBL1-VarO domain (a DBL1α1.6 
type) and the VarO Head protein (double domain 
DBL1α–CIDRγ) have been determined by X-ray crys-
tallography (PDB entries 2xu0 and 2yk0 respectively) 
[20, 28]. The DBL1-VarO single domain, which was 
cleaved after residue R69 during expression and purifi-
cation of the recombinant protein, did not bind to RBC 
[28]. The DBL1-VarO domain of the Head construct, 
by contrast, was produced intact and efficiently bound 
RBC [20]. Comparison of these two structures shows 
that the R69 cleavage leads to a significant conforma-
tional change in the polypeptide segment comprising 
the C-terminal region of NTS, the N-terminal region 
of subdomain 1 and the hinge connecting these two 
regions (in total, the segment between residues T51 
and K95, inclusive) (Fig.  6a, b). Although this region 
Fig. 4 Titration of the capacity to inhibit formation of Palo Alto 89F5 VarO rosettes (a) or disrupt Palo Alto 89F5 VarO rosettes (b). The capacity of 
each mAb to inhibit rosette formation or disrupt rosettes was studied as described in the “Methods” section. Assays were done on at least three 
distinct parasite cultures. A typical example is shown. The rosetting rate for each mAb concentration was recorded by microscopic examination and 
the results expressed as percent of rosettes observed in a test culture compared to a culture done in the absence of added mouse or rabbit reagent
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Fig. 5 ELISA titration curves of individual mAbs on a panel of recombinant mutants of the DBL1 adhesion domain. a–d ELISA on eDBL1, eHead and 
Mut11 as well as mutants Mut2, Mut4 and parental eDBL1‑s. e–h ELISA on eDBL1‑s and Factor Xa‑cleaved Mut10 and eDBL1. The following anti‑
DBL1 mAbs were used: D15‑50 (a, e), BD20E4 (b, f), E20‑76 (c, g) and BDEE10 (d, h)
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could be completely traced in the electron density of 
the intact DBL1-VarO domain (PDB entry 2yk0), signif-
icant parts of this region were disordered in the cleaved 
protein and could not be built (PDB entry 2xu0). As 
this region is adjacent to the blood group binding sites 
on DBL1-VarO predicted by docking calculations, 
abrogation of RBC binding in the cleaved domain is 
most likely due to the conformational change (Fig.  6). 
Since the inhibitory and rosette-disrupting mAb D15-
50 binds to the intact Head construct but poorly to the 
cleaved DBL1-VarO protein (See Table  3, Mut10fXa), 
this antibody is affected by the structural changes aris-
ing from the R69 cleavage. In addition, point muta-
tions affecting the binding of D15-50 are displayed 
by Mut2 (K95A, K166A and K179A), which lie to one 
side of the predicted blood group A and blood group 
B binding sites, adjacent to the region that undergoes 
the conformational change induced by the R69 cleav-
age (Table  3; Fig.  6c, d). By contrast, BD20E4, a very 
effective rosette-disrupting mAb, binds less efficiently 
to Mut4, whose mutations (K226A, K227A and K230A) 
lie on the opposite side of the ABO blood group anti-
gen binding site (Table 3; Fig. 6c, d). This is compatible 
with the observation that binding by BD20E4 is unaf-
fected by the R69 cleavage and does not compete with 
the binding of D15-50. Although both Mut2 and Mut4 
also carry the mutation K87A, the mutant Mut-K87, 
with only the K87A amino acid change, is fully recog-
nized by these two mAbs (Table  3) and thus does not 
contribute to the epitope of either mAb. Of note, nei-
ther Mut2 nor Mut4 affected the binding of heparin, 
whose binding site on DBL1-VarO is predicted to be on 
Table 3 Binding ratio of four anti DBL1-VarO mAbs on a set of recombinant domains with differing length and mutated 
residues
ND not determined
a Predicted N-glycosylation sites mutated (NxT/S to NxA)
b MBP-Mut10 was cleaved by Factor Xa located at the cloning site and at the internal site introduced at positions 66–69 (IEGR)
c DBL protein sequence identical to Mut10, but the cloning site (encoding a Factor Xa cleavage site) was changed for a thrombin cleavage site
d From ref [22]
e From ref [28]
f The mean ratio of reactivity was calculated as the mean of ratio to the parent protein observed for 3 successive dilutions in the linear part of the ELISA titration 
curves. The average ratio is shown for the proteins tested in 2-3 independent experiments
Ref Protein PfEMP1-VarO  
Residues
(No Cys)
Mutationsa RBC  
bindingd
Fold increase  
Kd heparine
D15-50 E20-76 BD20E4 BDEE10 No tests
Ratio to eDBL1f
[27] eDBL1 2–487 (20) # +++ ND 1 1 1 1
[28] eDBL1‑s 2–471 (18) # K87A ++ 1 0.95 0.92 0.27 1.01 3
[22] eDBL1‑swt 1–471 (18) Wild type ++++ ND 1 1 0.3 1 2
[22] eHead 2–716 (31) # +++++ ND 1.4 1.5 1.3 1.8 2
Ratio to parent eDBL1f
[22] Mut K87 2–487 (20) # K87A ++++ ND 0.93 0.85 0.90 0.87 1
[22] Mut10fXab 2–487 (20) # G66I Y67E V68G Nil ND 0.45 0.12 1.05 1.10 2
[22] Mut11c 2–487 (20) # G66I Y67E V68G +++ ND 1.30 1.30 1.00 1.20 1
Ratio to parent eDBL1‑sf
[28] Mut1 2–471 (18) # K87A K2A0 K32A 
K40A
++ 115 0.66 0.67 0.79 0.76 2
[28] Mut2 2–471 (18) # K87A K95A K166A 
K179A
Nil 1 0.47 0.36 1.05 1.1 3
[28] Mut3 2–471 (18) # K87A K423A 
K424A K451A 
K456A
++ 218 0.94 0.91 1.1 0.85 2
[28] Mut4 2–471 (18) # K87A K226A 
K227A K230A
Nil 11 0.94 0.84 0.42 0.45 3
[28] Mut5 2–471 (18) # K87A K404A 
K407A K410A
++ 1 0.85 0.77 1.03 0.96 2
[22] Mut8 2–471 (18) # K87A R64A Y67A 
R69A
Nil ND 0.87 1.40 0.85 0.97 1
[22] Mut9 2–471 (18) # K87A T88A Y90A 
E92A
+ ND 1.03 1.05 0.90 1.00 1
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the opposite side of the domain [28]. The ELISA results 
and structural epitope mapping thus present a coherent 
picture; the two potent rosette-disrupting mAbs, D15-
50 and BD20E4, recognize two distinct epitopes adja-
cent to, but on opposite sides of, the predicted ABO 
blood group antigens-binding site.
Discussion
This work investigated specificity and functionality of 
mAbs obtained from animals immunized with recombi-
nant domains from PfEMP1-VarO. MAbs raised to four 
different PfEMP1-VarO domains were obtained; they 
reacted with the surface exposed PfEMP1-VarO protein 
and appear representative of the corresponding poly-
clonal sera with regard to potency of surface reactivity 
and inhibition of adhesion.
Potent mAbs were obtained against DBL1 that effi-
ciently inhibited formation of rosettes down to quite 
low concentrations and efficiently reversed rosetting. 
This confirms previous data showing that polyclonal 
sera raised to the correctly folded, functional adhesion 
domain efficiently block and disrupt Palo Alto VarO 
rosetting [20, 33]. MAbs BD20E4, D15-50 and E20-76 
were more potent inhibitors, and mAbs BD20E4 and 
D15-50 were more potent disrupters, than the polyclonal 
rabbit IgG raised against bDBL1 (Fig. 4). This is remark-
able as VarO rosettes are large (called giant rosettes by 
others [38, 39]) and involve strong interactions that can-
not be mechanically disrupted, in contrast to other roset-
ting parasites such as IT4R29 [23, 40]. As such, these 
mAbs represent precious tools to dissect key molecular 
interactions involved in rosetting. It is worth noting that 
design of the recombinant domain is important to the 
induction of potently blocking antibodies. Indeed, anti-
bodies elicited against a PfEMP1-VarO DBL1 domain 
lacking a stretch of 89 C-terminal residues compared 
to DBL1 expressed here (and missing 5 out of 20 Cys 
residues, thereby preventing formation of the Cys324–
Cys442, Cys354–Cys470, Cys377–Cys467 and Cys477–
Cys483 disulfide bonds) only partially inhibited Palo Alto 
VarO rosetting [41].
Recently, rosetting was shown to occur in the absence 
of PfEMP1. In parasites in which PfEMP1 trafficking to 
the red cell membrane was impaired by disruption of the 
Pfmahrp1 gene, variant STEVOR proteins were shown to 
mediate rosetting through binding to glycophorin C [42]. 
A-RIFINs were identified as a mediator of rosetting involv-
ing binding to blood group A antigens, when PfEMP1 
was removed by trypsin treatment or blocked by adding 
PfEMP1-specific antibodies [41]. This led some authors to 
conclude that A-RIFINs “are conceivably the main ligand 
of this host-parasite interaction” and that it is possible 
Fig. 6 Localization of the mutations impairing binding of inhibi‑
tory mAbs on the DBL1 domain on the DBL1α1‑VarO structure. a, 
b Superposition of the DBL1‑VarO crystal structures from the intact 
and cleaved domains (PDB entry codes 2yk0 and 2xu0, respectively), 
shown in ribbon representation. The intact domain is shown in brown 
and the cleaved domain is shown in grey. The region undergoing the 
conformational change (from residues T51 to K95) is shown in red for 
the intact domain and in blue for the cleaved domain; only 16 of the 
45 residues comprising this segment could be traced in the cleaved 
domain. This region forms one side of the binding sites for the blood 
group glycans that were predicted by docking calculations. The A 
and B blood group trisaccharides are shown as molecular surface rep‑
resentations in yellow and green, respectively. a is viewed from above 
the glycan binding site and b is rotated by 90° about a vertical axis. 
c, d. Positions of point mutations in the intact DBL1‑VarO (PDB entry 
code 2yk0) that affect the binding of mAbs, showing the docked 
blood group trisaccharides, as in views (a, b). The structure is shown 
as a semi‑transparent molecular surface with the ribbon representa‑
tion. Mutations of the Mut2 protein are in blue and those of Mut4 are 
in purple. (Mutated residue K87, which is common to Mut2 and Mut4 
is not shown as this does not affect the binding of either the mAbs or 
the blood group glycans; see text and Table 3). The region implicated 
in the conformational change upon cleavage is shown in red and 
the side chain of residue R69, shown as spherical atoms, is cyan. c is 
viewed from above the glycan binding site and d is rotated by 90° 
about a vertical axis
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that “PfEMP1 might work as an accessory or alternative 
interaction to reinforce by multiple contact points these 
protein-carbohydrate interactions that are usually weak” 
[43]. The potent rosette blocking and disruption capacity 
shown here for single mAbs reacting solely with PfEMP1 
in Palo Alto 89F5 VarO extracts (Fig. 3) does not support 
such conclusions, but rather indicates that when PfEMP1 
is expressed and surface-exposed, i.e., the normal condi-
tion of P. falciparum parasites, it is a major determinant 
of rosetting as PfEMP1-specific mAbs readily inhibit and 
disrupt rosettes.
Analysis of reactivity to a panel of constructs showed 
that some DBL1 mutations reduced but did not abol-
ish binding of the mAbs, although they did completely 
abolish RBC binding of the recombinant domain [20]. 
MAbs interfering with rosetting bound to two distinct 
regions on the surface of the DBL1 domain (Fig. 6) in 
proximity to the blood group trisaccharide binding site, 
which has been localized by computer docking and 
site-directed mutagenesis to a restricted surface area 
situated at the interface of subdomain 1 and subdomain 
2 in the vicinity of the NTS-DBL1α1 hinge region [20]. 
This is consistent with inhibition of rosetting by impair-
ing access to the RBC-binding site. The close proxim-
ity or partial overlap of the BD20E4 epitope with the 
RBC-binding site is reminiscent of findings observed 
for the binding site of the 24E9 Fab mAb, which over-
laps with the ICAM-1 binding site on the surface of the 
DBLβ3-D4 domain of PfEMP1-PFD1235w [44]. None of 
the anti-DBL1 VarO mAbs appear to bind to the region 
of subdomain 3 identified as the binding site of mAbs 
that potently disrupted FCR3S1.2 (alias IT4Var60) or 
R29 (alias IT4Var9) rosettes [45] located in a different 
region of the DBL1 surface (see Additional file 4: Figure 
S3). Interestingly, the RBC-binding site of the DBL1α-
IT4var60 domain has recently been localized adjacent 
to the RBC-binding site of DBL1α-VarO [46]. Moreo-
ver, mapping of human antibody reactivity with short 
linear-peptides of DBL1α-FCR3S1.2 indicated the pres-
ence of epitopes recognized by anti-rosetting antibod-
ies within subdomains 1 and 2 [47]. Although these 
data are consistent with the findings reported here, it 
is possible that other parts of the DBL1 domain con-
tribute to optimal display of the binding site and as 
such, can be targeted by rosette disrupting antibod-
ies. It is worth noting that both titres and OD values 
observed with BD20E4 decreased when the constructs 
lacked the C-terminal residues forming the hinge with 
CIDR, which are located far from the RBC-binding area 
[20]. The conservative conclusion from the work pre-
sented here is that mAbs displaying a potent rosette-
inhibition and rosette-disruption activity bind with 
non-overlapping sites located close to the RBC-bind-
ing site area, but this does not exclude contribution of 
additional regions of the molecule or existence of addi-
tional important epitopes.
Most mAbs studied here targeted reduction-sensitive 
epitopes, including mAbs M21-17 and M21-30, which 
had an unusual profile as they recognized reduction-sen-
sitive epitope(s) on both PfEMP1-VarO and the recom-
binant DBL1 domain but did not stain the VarO iRBC 
surface. The possibility that the binding sites are sur-
face-exposed but masked by some serum component is 
ruled out by the lack of reactivity with the PfEMP1-VarO 
protein on immunoblots of Palo Alto 89F5 VarO SDS-
extracts (Fig. 3). This indicates that the epitopes in ques-
tion depend on the proper formation of disulfide bonds 
and the correct folding of the protein but are lost upon 
iRBC surface display.
Heparin and sulfated glycosaminoglycans are potent 
inhibitors of Palo Alto VarO rosetting [27] as well as of 
multiple rosetting types [24, 25, 46, 48–51]. This sug-
gests the presence of some common motif/epitope 
shared by rosette-forming parasites, which constitutes 
an attractive intervention target. None of the mAbs iso-
lated here proved sensitive to the presence of mutations 
that drastically reduced heparin binding [28]. Interest-
ingly, two potent FCR3S1.2 rosette-disrupting mAbs 
also failed to map to the heparin-binding area of the 
expressed PfEMP1-IT4var60 molecule [46]. Although 
these properties prevent dissecting the molecular basis 
of VarO-heparin binding using the available inhibitory 
mAbs, it confirms that the heparin-binding site and the 
RBC-binding sites are located far from each other on the 
DBL1-VarO surface.
There was some relationship between ELISA titres 
and surface IFA titres and MFImax. The mAb with 
the lowest titre (G8-49) had the lowest surface reac-
tivity, and interestingly, both ELISA titres and surface 
reactivity were lower than mAb N6-37, also a CIDR 
binder. In contrast, the mAbs with the highest ELISA 
titres (the anti-DBL2 mAbs B12-42 and B12-15 and 
the anti-DBL4 mAb D18-94) did not have the highest 
IFA titres and MFImax. This may reflect reduced acces-
sibility of the individual domains on the iRBC surface 
compared to the N-terminal domains. Previous find-
ings showed limited quantitative relationship between 
ELISA reactivity and surface staining with polyclonal 
sera [30, 33]. Interestingly however, there was a good 
relationship between MFImax and rosette inhibition. 
The two most potent disrupters, BD20E4 and D15-50 
had the highest IFA titres and the highest MFImax, 
mAbs D15-68 and E20-76 had intermediate MFImax 
and rosette inhibition potency, while BDEE10, the least 
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efficient inhibitor had the lowest MFImax. In contrast, 
there was poor relationship of MFImax and/or IFA 
titres with the rosette disruption potency (Table 2). The 
rosette-inhibition assay was more sensitive than rosette 
disruption, confirming data from other rosetting types 
[15]. However, there was no obvious relationship 
between the two assays. This is particularly striking for 
mAbs BD20E4, D15-50 and E20-76, which had simi-
lar rosette inhibition profiles and dissimilar rosette-
disruption capacity. Whether this reflects difference 
in binding affinity for PfEMP1-VarO or different lev-
els of steric hindrance within the cellular aggregates 
remains to be established. Affinity of the various mAbs 
for DBL1-VarO was not explored here, because of the 
unclear relevance of binding constants for the recom-
binant antigen with regard to binding to the iRBC 
surface-exposed PfEMP1-VarO. PfEMP1 is displayed 
as a multimodular protein (downstream modules may 
influence binding of inhibitory mAbs) and moreover by 
a specialized membrane structure, the knob, where it 
is presented at a high concentration. Moreover, rosette 
inhibition and rosette disruption involve impairment 
or displacement of interactions with long blood group 
saccharides expressed on a variety of RBC surface mol-
ecules and steric hindrance is an issue.
Conclusions
The set of anti-VarO mAbs described here will facili-
tate future studies to design soluble rosetting inhibi-
tors and dissect the specificity of human responses to 
the VarO antigenic variant, that is commonly recog-
nized by humans living in malaria-endemic areas [13, 
29, 30]. Importantly, all mAbs failed to react with the 
iRBC surface of related rosette-forming variants such 
as R29/IT4var9 or 3D7/PF13_0003, like polyclonal anti-
bodies raised to the cognate DBL1 domains [30]. This 
confirms the variant-specific surface reactivity observed 
with a panel of mAbs to the R29/IT4var9 or FCR3S1.2/
IT4var60 DBL1 proteins [45]. In line with this, none of 
the anti-VarO mAbs reacted with the region of subdo-
main 2 shown to induce variant-transcending antibod-
ies [52], which is distant from the binding site areas of 
the anti-VarO mAbs and partially masked by the surface 
exposed NTS-VarO domain (see Additional file  4: Fig-
ure S3). The identification of a restricted surface area as 
the binding site of inhibitory mAbs opens the way for 
fine mapping of the variant-specific interactions of the 
inhibitory mAbs with the DBL1 domain. This informa-
tion will be essential to better understand the specificity 
of antibodies elicited by infection in humans [13, 29, 30, 
47] and determine which natural responses should be 
harnessed by vaccination and which additional specifi-
cities should be elicited by vaccination.
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